

From: [REDACTED]
To: [BRETON Thierry \(CAB-BRETON\)](#)
Cc: [CAB BRETON CONTACT](#); [REDACTED]; [REDACTED]
Subject: AZD1222 – Lancet Publication of PhIII interm analysis
Date: mardi 8 décembre 2020 17:30:05
Attachments: [Lancet Publication.pdf](#)

Dear Commissioner Breton,

I am pleased to inform you that peer-reviewed results from an interim analysis of Phase III AZD1222 trials have been published in *The Lancet* today. Further to the announcement of positive high-level results on 23 November, the publication demonstrates that the vaccine is safe and effective at preventing symptomatic COVID-19 and protects against severe disease and hospitalisation. This is the first independent peer-reviewed publication of late-stage results of coronavirus vaccine trials.

Please find the publication attached and [here](#) the official company announcement with further information. More data will continue to accumulate through ongoing global clinical trials, refining the analysis and characterising vaccine efficacy over a longer period of time.

Please do not hesitate to reach out should you have any questions.

Best regards,

[REDACTED]
[REDACTED]
AstraZeneca | Neuhofstrasse 34, 6340 Baar
E: [REDACTED] [@astrazeneca.com](mailto:[REDACTED]@astrazeneca.com)

Confidentiality Notice: This message is private and may contain confidential and proprietary information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this message is not permitted and may be unlawful.